Sort   by:  
 Page size 
UnknownThe role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study.
Not available
S-EPMC7163789 | biostudies-literature
UnknownCombined pre-treatment and middle-treatment Epstein-Barr virus DNA load contributes to prognostication and treatment modification in nasopharyngeal carcinoma patients.
Not available
S-EPMC10771739 | biostudies-literature
UnknownDifferent prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.
Not available
S-EPMC4390333 | biostudies-literature
UnknownIndividualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Not available
S-EPMC6675745 | biostudies-literature
UnknownExtract of Acalypha australis L. inhibits lipid accumulation and ameliorates HFD-induced obesity in mice through regulating adipose differentiation by decreasing PPARγ and CEBP/α expression.
Not available
S-EPMC7955518 | biostudies-literature
UnknownIdentification of a Susceptible and High-Risk Population for Postoperative Systemic Inflammatory Response Syndrome in Older Adults: Machine Learning-Based Predictive Model.
Not available
S-EPMC11624453 | biostudies-literature
UnknownA rapid and naked-eye methicillin resistant <i>Staphylococcus aureus</i> screening method based on CRISPR/Cas12a and hybridization chain reaction.
Not available
S-EPMC12309411 | biostudies-literature
UnknownDetermining the optimal duration of oral adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Not available
S-EPMC12238370 | biostudies-literature
UnknownCytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience.
Not available
S-EPMC7789459 | biostudies-literature
UnknownSafety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial.
Not available
S-EPMC10022191 | biostudies-literature
Sort   by:  
 Page size